Annual Drug Patent Expirations for EVOMELA
Evomela is a drug marketed by Acrotech and is included in one NDA. It is available from one supplier. There are four patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for EVOMELA.
This drug has seventy-four patent family members in eighteen countries.
The generic ingredient in EVOMELA is melphalan hydrochloride. One supplier is listed for this compound. Additional details are available on the melphalan hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
